Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics ($ELVN), sold about $2.4 million in company shares across three open market transactions in the past year. Her latest sale occurred on March 10, 2026. These ELVN insider sales rank her 3,136th out of 11,678 individuals by total value, trailing the average of $8.6 million over roughly 6.4 trades per insider. She reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 40000 | $0.00 | 136,268.0000 | 62,093,795 | 22.69% | 0.06% |
| March 25, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 40000 | $2.48 | 65,000.0000 | 62,093,795 | 160.00% | 0.06% |
| March 25, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 40000 | $35.10 | 25,000.0000 | 62,093,795 | 61.54% | 0.06% |
| March 17, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 5000 | $0.00 | 176,268.0000 | 62,093,795 | 2.76% | 0.01% |
| March 17, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 5000 | $2.48 | 30,000.0000 | 62,093,795 | 20.00% | 0.01% |
| March 17, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 5000 | $27.76 | 25,000.0000 | 62,093,795 | 16.67% | 0.01% |
| March 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 29871 | $2.48 | 54,871.0000 | 62,093,795 | 119.48% | 0.05% |
| March 10, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 10129 | $30.19 | 25,000.0000 | 62,093,795 | 28.83% | 0.02% |
| March 10, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 10129 | $0.00 | 181,268.0000 | 62,093,795 | 5.29% | 0.02% |
| March 10, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 10129 | $2.48 | 35,129.0000 | 62,093,795 | 40.52% | 0.02% |
| March 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 29871 | $30.02 | 25,000.0000 | 62,093,795 | 54.44% | 0.05% |
| March 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 29871 | $0.00 | 191,397.0000 | 62,093,795 | 13.50% | 0.05% |
| Feb. 17, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 45000 | $2.48 | 70,000.0000 | 62,093,795 | 180.00% | 0.07% |
| Feb. 17, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 45000 | $0.00 | 221,268.0000 | 62,093,795 | 16.90% | 0.07% |
| Feb. 17, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 45000 | $26.17 | 25,000.0000 | 62,093,795 | 64.29% | 0.07% |
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | A | Common Stock | 25000 | $0.00 | 25,000.0000 | 62,093,795 | 9999.99% | 0.04% |
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 62,093,795 | 9999.99% | 0.24% |
| June 5, 2025 | Kura Oncology, Inc. | $KURA | Collins Helen Louise | Not found | A | Option to purchase common stock | 28500 | $0.00 | 28,500.0000 | 86,161,000 | 9999.99% | 0.03% |
| June 5, 2025 | IO Biotech, Inc. | $IOBT | Collins Helen Louise | Not found | A | Stock Option (Right to Buy) | 35144 | $0.00 | 35,144.0000 | 65,880,914 | 9999.99% | 0.05% |
| Feb. 6, 2025 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | A | Stock Option (right to buy) | 171000 | $0.00 | 171,000.0000 | 47,072,532 | 9999.99% | 0.36% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 816 | $0.00 | 266,268.0000 | 48,267,458 | 0.31% | 0.00% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 816 | $2.48 | 816.0000 | 48,267,458 | 9999.99% | 0.00% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 816 | $30.00 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| June 6, 2024 | IO Biotech, Inc. | $IOBT | Collins Helen Louise | Not found | A | Stock Option (Right to Buy) | 45642 | $0.00 | 45,642.0000 | 0 | 9999.99% | 0.00% |
| June 5, 2024 | Kura Oncology, Inc. | $KURA | Collins Helen Louise | Not found | A | Option to purchase common stock | 26000 | $0.00 | 26,000.0000 | 73,229,000 | 9999.99% | 0.04% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Stock Option (right to buy) | 20000 | $0.00 | 267,084.0000 | 35,546,215 | 6.97% | 0.06% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | S | Common Stock | 20000 | $25.07 | 0.0000 | 35,546,215 | 100.00% | 0.06% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | Common Stock | 20000 | $2.48 | 20,000.0000 | 35,546,215 | 9999.99% | 0.06% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | CHIEF MEDICAL OFFICER | A | Stock Option (right to buy) | 185000 | $0.00 | 185,000.0000 | 35,546,215 | 9999.99% | 0.52% |
| May 31, 2023 | Kura Oncology, Inc. | $KURA | Collins Helen Louise | Director | A | Option to purchase common stock | 26000 | $0.00 | 26,000.0000 | 66,990,000 | 9999.99% | 0.04% |
| April 4, 2023 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | Chief Medical Officer | A | Stock Option (right to buy) | 206000 | $0.00 | 206,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Collins Helen Louise | Chief Medical Officer | A | Employee Stock Option (right to buy) | 287084 | $0.00 | 287,084.0000 | 0 | 9999.99% | 0.00% |